Utility of Spherical Human Liver Microtissues for Prediction of Clinical Drug-Induced Liver Injury


1 Drug Safety and Metabolism, †Discovery Sciences, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, and Cambridge Science Park, Cambridge, Cambridgeshire, CB4 0WG, United Kingdom
2 Investigative Toxicology, Department of Safety Assessment, Genentech, Inc. 1 DNA Way, South San Fransisco, CA, 94080, USA
3 InSphero AG, Wagistrasse 27, 8952 Schlieren, Switzerland

†Corresponding author: Alison Foster, Drug Safety and Metabolism, AstraZeneca, Cambridge Science Park, Cambridge, Cambridgeshire, CB4 0WG, United Kingdom email address: alison.foster2@astrazeneca.com
Supplemental Figure: S1

Supplemental Fig. S1. Exemplary graphs (randomly chosen) of dose-response curves obtained from 2D PHH (●) and 3D hLiMT (■). Four compounds are displayed from each DILI-severity category.